OmniGuide Holdings
BOSTON / ACCESSWIRE / February 22, 2024 / OmniGuide™ Holdings (OGH) and UROTECH® (part of the Medi-Globe Group, a subsidiary of DCC plc) have announced a new partnership to strengthen UROTECH's technology portfolio for urologists. As part of the collaboration, the partnership will work with urologists to build a global network for RevoLix™ HTL (Hybrid Thulium Laser Therapy) specifically for kidney stones and benign prostatic hyperplasia (BPH).
UROTECH is one of the leading medical technology manufacturers in the field of minimally invasive urology. The treatment of kidney stones is at the heart of UROTECH's work, which is committed to the highest quality standards for its products and clinical experience. As a determined and reliable medical partner, UROTECH supports the daily work of urologists.
Surgeons and nurses recognize OmniGuide's ability to deliver advanced solutions for some of the most important surgical therapies in urology. OmniGuide's innovative focus on robotics, precision light therapies and biosensing software enables the company to cover a wide range of urological procedures and reduce complications every day.
The aim of the global collaboration is to support future surgical trends by providing access to data and insights for urological decisions. The partnership will accelerate these efforts as two global companies work toward a common goal and bring their surgical expertise.
OmniGuide Urology will support projects with UROTECH including:
- Scaling global capacity for Kidney Stones and BPH Treatments through the newly launched RevoLix™ HTL Hybrid Thulium Laser.
- User-centered strategies for existing urologists, delivering solutions to better support a great clinical experience.
- Increase advocacy through partnering and establishing a forum in urology.
- Developing a biosensing software platform in partnership with the OmniGuide™ Institute for Biomedical Innovation.
"UROTECH is known for its customer focus and the user-centric development and distribution of innovative solutions for urologists worldwide. The partnership with OmniGuide fits into this mindset, to make the revolutionary all-in-one RevoLix HTL laser technology and its great benefits available to our customers," said Dr. Markus Schönberger, Director Business Development and Head of the Strategic Business Unit Urology of the Medi-Globe Group.
"Biosensing Innovation is increasing both the need to collaborate and share data," said M.T. Henderson CEO OmniGuide Holdings™ (OGH). "Solutions that connect outcomes with recent technology are at the core of our collective purpose. We are proud to partner with UROTECH to expand our shared vision of helping to improve patient lives, fueled by innovation-forward therapies."
About OmniGuide Holdings
Headquartered in Billerica, Massachusetts, USA, OmniGuide is a leader in the design, development, and marketing of patient safety-focused advanced energy surgical tools to benefit clinicians and their patients. OmniGuide is a privately held company, majority owned by an investment fund managed by OrbiMed Advisors LLC.
About UROTECH
UROTECH is a Medi-Globe Group company, which is part of DCC Healthcare, one of three divisions of DCC plc, an Ireland-based FTSE 100 listed company. The head office of UROTECH is in Achenmühle in Chiemgau, Bavaria, south of Munich, Germany.
The Medi-Globe Group is an innovative, fast-growing, and internationally oriented group of medical technology companies in the fields of urology, gastroenterology and pneumology.
UROTECH serves its customers including university hospitals, specialist clinics, and special medical facilities in 50 countries worldwide.
Media Contact
Iris Schäfer Medi-Globe Group: press@medi-globe.de
Tullio Cappelletto OmniGuide Holdings: Tcappelletto@omni-guide.com
Contact Information
Iris Schäfer
press@medi-globe.de
Tullio Cappelletto
tcappelletto@omni-guide.com
SOURCE: OmniGuide Holdings (OGH)
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata to Report Third Quarter 2025 Results16.10.2025 14:30:00 CEST | Press release
NEW YORK, NY, AL / ACCESS Newswire / October 16, 2025 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Third Quarter 2025 results after the market closes on Thursday, November 6, 2025. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 42719 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available for seven days following the conference call, and Webcast replay will be available for 30 days following the c
Karbon-X Corp. Reports Q1 2026 Revenue Growth and Strengthened Financial Position16.10.2025 14:00:00 CEST | Press release
Revenue reached $35.7 million, marking a 27,883% year-over-year increase driven by accelerated trading activity, and the continued expansion of Karbon-X's global carbon operations. CALGARY, AB / ACCESS Newswire / October 16, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or "the Company"), a vertically integrated climate solutions company, today announced financial results for the first quarter ended August 31, 2025, marking record revenue growth and continued execution of its strategic plan. The full filing is available under the Company's profile on OTC Markets at www.otcmarkets.com/stock/KARX/overview Karbon-X's Q1 2026 results underscore its accelerating growth trajectory and strong execution across all areas of its business. Q1 2026 Highlights Revenue Growth Karbon-X delivered transformational top-line growth as its carbon trading operations scaled globally. Revenue reached $35.7 million, up 27,883% year-over-year compared to $127,429 in Q1 2025. Growth was driven by the successfu
RelyEZ Unveils VentureEdge 800: Next-Generation 800 V AC Energy Storage System Tailored for Europe16.10.2025 08:20:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / October 16, 2025 / RelyEZ Energy Storage proudly announces the launch of its latest innovation, VentureEdge 800, a next-generation 800 V AC battery energy storage system (BESS) designed to meet Europe's evolving grid requirements. The launch coincides with RelyEZ's participation as a Gold Sponsor at the Energy Storage Global Conference (ESGC 2025) in Brussels, underscoring its commitment to supporting the region's clean energy transition with cutting-edge, bankable storage technologies. A New Standard for European Grid Compatibility Across Europe, most PV and wind installations operate on 0.8 kV/15 kV transformer infrastructure, while conventional 0.4 kV PCS systems require additional step-up transformers - increasing cost, space, and energy loss. VentureEdge 800 eliminates this layer entirely, offering direct 800 V AC connectivity for seamless integration with existing assets. This forward-looking design translates into: 5-15 % CAPEX savings through re
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models16.10.2025 07:00:00 CEST | Press release
Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions. High-quality biological patient data, enriched and integrated for use by AI agents. PARIS, FRANCE, GB / ACCESS Newswire / October 16, 2025 / Owkin today announces the launch of K Pro, its co-pilot bringing advanced agentic AI to biomedical research and drug development. K Pro helps pharmaceutical companies and biotechs make smarter decisions across the discovery and development pipeline, increase clinical success rates, and deliver decision-grade, data-driven biological insights fast enough to change program trajectories.Owkin K Pro Owkin K Pro - the Agentic AI Co-Pilot for Biopharma Built on a decade of Owkin's AI innovation and in close collaboration with leading academic and industry partners, K Pro is a scientist-first co-pilot, accessible to both researchers and executives. Through natural language interaction, users can ask complex biological questions and receive
Compliance Couture: How SMX and CETI are Changing the Rules for Fashion Sustainability (NASDAQ: SMX)15.10.2025 19:10:00 CEST | Press release
NEW YORK, NY, NY / ACCESS Newswire / October 15, 2025 / Global fashion brands require a single, essential ingredient to thrive: trust. Trust that its product is genuine, trust that the craftsmanship is authentic, and trust that the values behind the brand align with the ones it promotes. From Paris ateliers to fast-fashion retailers, every label's reputation depends on that same promise of quality, consistency, and credibility. But the world has changed. Supply chains have gone global. Sustainability has become a shareholder demand. And the old way of proving trust - through reputation alone - no longer cuts it. Today, trust must be earned through evidence. That's where SMX (NASDAQ:SMX) and CETI, the European Center for Innovative Textiles, come in. Together, they've created something fashion has needed for years: proof. Their industrial-scale collaboration embeds molecular-level traceability directly into textile fibers, giving every material its own unbreakable digital fingerprint. I
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom